Institut Biochimique

What Institut Biochimique does

IBSA Institut Biochimique SA is a privately held Swiss pharmaceutical company headquartered in Lugano, Switzerland, founded in 1945 by Arturo Licenziati. The company develops formulation-optimized dosage forms of already-known active ingredients and operates across ten therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular medicine, aesthetic medicine, dermatology, uro-gynecology, cardiometabolic medicine, respiratory system, and consumer health. Production is anchored in Switzerland (Lugano-Pazzallo headquarters and Cadempino business-operations site), with Swiss manufacturing positioned as a quality signal in regulated markets.

The company's go-to-market is a wholly-owned direct distribution model: IBSA operates 20 subsidiaries spanning Europe (Austria, Baltic States/Nordic, Belgium, Czechia, France, Germany, Hungary, Iberia, Italy, Netherlands, Poland, Slovakia, Switzerland, Turkey, UK), Asia (China, Hong Kong, Singapore), and the USA. Products are present in 90+ countries across five continents, including the Middle East, Far East, and North Africa. The firm employs more than 2,500 people globally and serves healthcare providers (physicians and specialists) and patients across each therapeutic area, with a horizontal segmentation strategy that emphasizes breadth of portfolio rather than concentration in any single category.

Revenue is generated primarily through one-time sales of pharmaceutical products; pricing is not publicly disclosed. Marketing is supported by the IBSA Foundation (scientific research grants and fertility-awareness campaigns), recurring branded events such as Coppa IBSA and StraLugano, and sponsorships including Casa dell'Hockey. The company operates a sustainability manifesto aligned with ESG objectives. No public-ownership, external-investor, or funding-round information is disclosed, and no M&A or restructuring activity is reported in the available data.

Name

Institut Biochimique

Legal name

IBSA Institut Biochimique SA

Website

https://ibsa.swiss

Company type

Private

Founded year

1945

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

IBSA is a privately held Swiss pharmaceutical company founded in 1945 that develops formulation-optimized dosage forms across ten therapeutic areas and distributes them in 90+ countries via 20 wholly-owned subsidiaries, employing more than 2,500 people globally.

Ownership category

akta.pro rank

Headquarters

HQ city

Lugano

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Pharmaceutical Products: Revenue generated from manufacturing and selling pharmaceutical products across 10 therapeutic areas including reproductive medicine, endocrinology, pain/inflammation, aesthetic medicine, dermatology, and consumer health.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

IBSA (Institut Biochimique SA) is a multinational Swiss pharmaceutical company that develops, manufactures, and distributes formulation-optimized dosage forms of already known active ingredients across 10 therapeutic areas, including reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynecology, cardiometabolic medicine, respiratory treatments, and consumer health. The company produces its pharmaceutical products in Switzerland and sells them through 20 wholly-owned subsidiaries to customers in 90+ countries.

Product overview

IBSA (Institut Biochimique SA) is a multinational Swiss pharmaceutical company founded in 1945, operating across 10 therapy areas. The company's product portfolio spans reproductive medicine, endocrinology, pain and inflammation management, bone and joint medicine, aesthetic medicine, dermatology, uro-gynecology, cardiometabolic conditions, respiratory treatments, and consumer health. The company serves over 90 countries with 20 subsidiaries in Europe, China, and the USA, employing more than 2,500 people worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• Reproductive Medicine

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Ferring Pharmaceuticals: Private Swiss specialty pharma headquartered near Lausanne with a heavy focus on reproductive medicine, uro-gynecology, and endocrinology — closely overlapping with IBSA's reproductive medicine, endocrinology, and uro-gynecology therapy areas and its direct-subsidiary European distribution model.
• Organon: Women's-health-focused pharma spun out of Merck, with franchises in reproductive health, dermatology, and respiratory — directly overlapping with IBSA's reproductive medicine, dermatology, and respiratory therapy areas.
• Gedeon Richter: Hungarian specialty pharma with strong women's health, CNS, and cardiometabolic franchises — directly overlapping IBSA's reproductive medicine, endocrinology, and cardiometabolic therapy areas with a similar mid-size European footprint.
• Almirall: Spanish specialty pharma with focus on dermatology and aesthetic medicine, both of which are core IBSA therapy areas. Mid-cap European pharma with comparable portfolio breadth and geographic reach.
• Stada Arzneimittel: Privately-held German mid-size pharma with broad specialty and generics portfolio across multiple therapy areas and direct European country subsidiaries — closely mirrors IBSA's privately-held, multi-therapy, subsidiary-led model.
• Recordati: Milan-based specialty pharma operating across multiple therapeutic areas including cardiometabolic and rare diseases, with a similarly diversified mid-size portfolio and European commercial footprint comparable to IBSA's structure.

Broad incumbents

• Viatris: Global generics and specialty pharma formed from Mylan and Upjohn, with broad off-patent portfolio that directly competes with IBSA's reformulation-led approach across multiple therapy areas.
• Sandoz (Novartis): Global generics and biosimilars business carved out of Novartis, offering broad formulation expertise across therapy areas overlapping with IBSA's portfolio, but operating at much larger scale and global reach.
• Teva Pharmaceutical Industries: Global generics and specialty leader with broad portfolio and large-scale manufacturing — competes with IBSA in formulation-improved generics and specialty pharma across overlapping therapy areas, but at vastly greater scale.

Regional players

• Aspen Pharmacare: South African-headquartered specialty and generics pharma with emerging-market focus and broad therapeutic-area portfolio — comparable business model and scale to IBSA but primarily serves African and Asia-Pacific geographies rather than Europe/China/US.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ibsa-swiss

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries18 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institut Biochimique